SEPTEMBER IS ANSWERING TTP's ADVOCACY MONTH IN CANADA.
Access depends on action from Canadians in all juridictions. You need to act.
Caplacizumab was approved by Health Canada in 2020, but is not funded for use in Canada despite being a standard of care in peer nations. Caplacizumab is our only immediate defence against the potentially life-altering blood clots that characterize a TTP crisis
A few simple actions you can take, will propell our cause forward. Without you, access may not be granted in your juridiction. With you, there is hope. You can tailor your committment to suit your schedule, but we need you, your friends, and your network. We are a rare and geographically dispersed patient population. We need each person touched by TTP (and their network of supporters) to have a voice, and we'll be there to support you every step.
Answering TTP Foundation strives to raise awareness for TTP and to represent a unified voice of action for the TTP community. Currently, our advocacy focus is to gain access to caplacizumab for treatment of TTP in Canada. To gain access in your province/territory we will need your help. This is a province-by-province/ territory-by-territory battle that will require a national network of advocates.
We try to obtain media coverage for all our events in order to raise the profile of TTP within our communities in an effort to speed diagnosis and save lives. Articles are listed within the Resource Links section of our website. If you are affiliated with the media and would like to focus a story on TTP please contact us.